Research ExplorerPublicationsPotential therapeutic effect of low-dose paclitaxel in melan...

Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study

Standard

Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. / Gebhardt, Christoffer; Simon, Sonja C S; Weber, Rebekka; Gries, Mirko; Mun, Dong Hun; Reinhard, Raphael; Holland-Letz, Tim; Umansky, Viktor; Utikal, Jochen.

In: CELL IMMUNOL, Vol. 360, 104274, 02.2021, p. 104274.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gebhardt, C, Simon, SCS, Weber, R, Gries, M, Mun, DH, Reinhard, R, Holland-Letz, T, Umansky, V & Utikal, J 2021, 'Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study', CELL IMMUNOL, vol. 360, 104274, pp. 104274. https://doi.org/10.1016/j.cellimm.2020.104274

APA

Gebhardt, C., Simon, S. C. S., Weber, R., Gries, M., Mun, D. H., Reinhard, R., Holland-Letz, T., Umansky, V., & Utikal, J. (2021). Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. CELL IMMUNOL, 360, 104274. [104274]. https://doi.org/10.1016/j.cellimm.2020.104274

Vancouver

Gebhardt C, Simon SCS, Weber R, Gries M, Mun DH, Reinhard R et al. Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. CELL IMMUNOL. 2021 Feb;360:104274. 104274. https://doi.org/10.1016/j.cellimm.2020.104274

Bibtex

@article{e308aee3778c45438e8e556be41ad55e,
title = "Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study",
abstract = "The low dose application of chemotherapeutic agents such as paclitaxel was previously shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells (MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three patients showed response to therapy (two partial responses and one stable disease). In responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of MDSCs in the peripheral blood and skin metastases. Furthermore, paclitaxel modulated levels of inflammatory mediators in the serum. In addition, responders displayed enhanced frequencies of tumor-infiltrating CD8+ T cells and their activity indicated by the upregulation of CD25 and TCR ζ-chain expression. Our study suggests that low-dose paclitaxel treatment could improve clinical outcome of some advanced melanoma patients by enhancing anti-tumor immunity and might be proposed for combined melanoma immunotherapy.",
author = "Christoffer Gebhardt and Simon, {Sonja C S} and Rebekka Weber and Mirko Gries and Mun, {Dong Hun} and Raphael Reinhard and Tim Holland-Letz and Viktor Umansky and Jochen Utikal",
note = "Copyright {\textcopyright} 2020 Elsevier Inc. All rights reserved.",
year = "2021",
month = feb,
doi = "10.1016/j.cellimm.2020.104274",
language = "English",
volume = "360",
pages = "104274",
journal = "CELL IMMUNOL",
issn = "0008-8749",
publisher = "Academic Press Inc.",

}

RIS

TY - JOUR

T1 - Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study

AU - Gebhardt, Christoffer

AU - Simon, Sonja C S

AU - Weber, Rebekka

AU - Gries, Mirko

AU - Mun, Dong Hun

AU - Reinhard, Raphael

AU - Holland-Letz, Tim

AU - Umansky, Viktor

AU - Utikal, Jochen

N1 - Copyright © 2020 Elsevier Inc. All rights reserved.

PY - 2021/2

Y1 - 2021/2

N2 - The low dose application of chemotherapeutic agents such as paclitaxel was previously shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells (MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three patients showed response to therapy (two partial responses and one stable disease). In responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of MDSCs in the peripheral blood and skin metastases. Furthermore, paclitaxel modulated levels of inflammatory mediators in the serum. In addition, responders displayed enhanced frequencies of tumor-infiltrating CD8+ T cells and their activity indicated by the upregulation of CD25 and TCR ζ-chain expression. Our study suggests that low-dose paclitaxel treatment could improve clinical outcome of some advanced melanoma patients by enhancing anti-tumor immunity and might be proposed for combined melanoma immunotherapy.

AB - The low dose application of chemotherapeutic agents such as paclitaxel was previously shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells (MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three patients showed response to therapy (two partial responses and one stable disease). In responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of MDSCs in the peripheral blood and skin metastases. Furthermore, paclitaxel modulated levels of inflammatory mediators in the serum. In addition, responders displayed enhanced frequencies of tumor-infiltrating CD8+ T cells and their activity indicated by the upregulation of CD25 and TCR ζ-chain expression. Our study suggests that low-dose paclitaxel treatment could improve clinical outcome of some advanced melanoma patients by enhancing anti-tumor immunity and might be proposed for combined melanoma immunotherapy.

U2 - 10.1016/j.cellimm.2020.104274

DO - 10.1016/j.cellimm.2020.104274

M3 - SCORING: Journal article

C2 - 33383383

VL - 360

SP - 104274

JO - CELL IMMUNOL

JF - CELL IMMUNOL

SN - 0008-8749

M1 - 104274

ER -